


# TRUDEAU

*on the Rise*




TRUDEAU INSTITUTE





## TRUDEAU IS:

A nimble, mission-directed research institute positioned to accelerate biomedical advances against life-threatening infectious diseases. Our special teams empower the pursuit of innovative solutions through efficient collaboration and select strategic partnerships.



# A New Era of Discovery

---

**Dear Friends,**



TODAY, IN OUR 135TH YEAR, Trudeau researchers are on the cusp of a new era of discovery. We have successfully recruited five new Ph.D.s, who will seek new treatments for drug-resistant tuberculosis, establish vaccine protocols to combat Zika and other emerging viruses, and build new expertise in the growing threat of tick-borne illnesses.

To fight most effectively as we deploy our superb special-focus teams, we've changed the very way we work. While we remain an independent biomedical research institution, we are intensively sharing our expertise with other world-class institutions to discover biomedical breakthroughs together. The growing breadth and depth of biomedical science demands this highly interactive, multi-disciplinary approach. By positioning Trudeau as a specialized biotechnology hub in a strategic partnership network, we can leverage the strengths of many institutions against infectious diseases—especially those that attack through the most common routes of infection and evade our immune defenses.

The core of our strategy, the Trudeau Research Network, is already expanding our reach and accelerating our progress. In the past two years, we have attracted partners from the Walter Reed Army Institute of Research, SUNY Upstate Medical University, Albert Einstein College of Medicine, the Texas Biomedical Research Institute and several other leading organizations to discover treatments for newly emergent diseases spread by mosquitoes and ticks, and to continue our long-running work in defusing respiratory-borne illness, especially tuberculosis and influenza.

A breakthrough in any of these areas will have untold impact on the human experience. Millions of people are infected, and die, from these diseases each year. These are the great public health challenges of our time—but we need your help to ensure these discoveries come to light. As Trudeau continues to rise, philanthropic support is urgently needed to accelerate our advances. We are actively seeking leadership funding for our Innovation Fund for Tuberculosis R&D, and our Innovation Fund for Tick-Borne Infections.

On behalf of all 60 of us at Trudeau—our growing team of dedicated researchers, technicians and support staff—I want to thank you for your generosity. I urge you to join with us and take action to leave a better world for generations to come.

Sincerely,

Atsuo Kuki, Ph.D.  
*President & Director*



**TB still remains  
the world's leading  
infectious disease**



**2 billion**

Number of  
people whose  
lungs have  
been infected  
by TB

**10 million**

New acute  
TB cases  
every year

**1.6 million**

Number of  
people killed  
by TB in  
2018

**458,000**

New  
multi-drug-  
resistant (MDR)  
TB cases  
in 2018

**4%-7%**

Percentage  
of developing  
nation GDP  
consumed  
by TB





# Continuing our Legacy

## When an old foe persists, Trudeau meets the challenge.

Some of the most important advances in tuberculosis research made in the 20th century resulted from work done at the Trudeau Institute.

Our job isn't done yet.

Between 2000 and 2018, 58 million people were cured of tuberculosis. But because of the sheer scale of this ongoing epidemic, and the lengthy, arduous treatment it requires, TB still remains the world's leading infectious disease: In 2018 alone, it killed 1.6 million people, more than due to HIV and influenza combined.

The most pressing challenge on that front is drug-resistant tuberculosis: tuberculosis bacteria that remain even after normal anti-TB treatment, resulting in a disease that is difficult to cure—fewer than a third of patients with the most virulent form of drug-resistant TB recover—and expensive to treat, with a typical 32-month course of treatment costing more than \$675,000.

We're deploying our long-standing expertise in tuberculosis, immunology, vaccines and genetics to fight this scourge—and deploying new fronts, also, in fields such as target-based drug discovery and computational chemogenomics (see story, following page). Trudeau is growing: We're adding new principal investigators and researchers in our TB program with academic, biotech/pharma and clinical research expertise, bolstering our professional staff who have decades of experience.

*In the Lab*

# Together Against TB



## Trudeau researchers turn to new methods in TB fight

Last year, public health experts estimate a half-million people were infected with a drug-resistant strain of tuberculosis, already the world's deadliest infectious disease. Behind this rapidly growing number of recalcitrant TB cases: Patients often don't complete the six-month, four-drug course of TB treatment, effectively allowing drug-resistant strains to emerge.

The result is a global health crisis that threatens to derail decades of advances in treating TB, and one for which scientists are scrambling for a faster, more potent—and less expensive—cure.

A pair of Trudeau scientists, Felix Sheinerman and Brian Weinrick, are spearheading an effort to identify drugs and molecules originally developed for other uses that may also be effective against tuberculosis. Sheinerman is using the latest computational methods to find good candidates, while Weinrick, an experienced TB researcher, is putting each through a rigorous evaluation.

And because many of the compounds they're investigating have already been tested for safety, it could drastically cut the time needed to get an improved treatment to patients.

Felix Sheinerman (left) and Brian Weinrick (right) are seeking new, faster tuberculosis treatments.

To Sheinerman, the math is on Trudeau's side. Of the tuberculosis bacterium's 4,000 genes, just 400 or so are critical to its ability to survive in human lungs.

Over the past century, though, more than 20,000 drugs have been developed and tested for safety in humans—some of which may prove fatal to the pathogen that causes TB. “The challenge is to say, ‘Look, even though that drug was never tested on this TB protein, it’s known to be active on a protein that is structurally very similar to one in TB,’” Sheinerman says.

Sheinerman's expertise, in a field known as computational chemogenomics, draws on 3D modeling techniques that can determine whether a particular molecule is likely to interact with any of those 400 TB proteins. If a match seems promising, Sheinerman alerts Weinrick, who then puts the compound through a battery of tests to see if it has real-world potential.

With just a few months of testing under their belts, as many as 10 percent of the compounds Sheinerman and Weinrick are investigating appear to be of interest. A typical drug discovery process, on the other hand, results in failure rates of 99 percent or more. “The existing drug discovery process is very inefficient,” Sheinerman says. “And that’s in large part the reason why modern drug discovery is not delivering.”

Seeing something merely interesting, though, is hardly the end of the discovery process. The team's job is to understand why a promising compound works, and refine it to be even more effective—ultimately leading to a treatment that can be patented, licensed to a pharmaceutical company, clinically tested and deployed. Ideally, they'd discover a drug that significantly shortens that half-year treatment period—even cutting it by 2 or 3 months, Weinrick says, “would be a huge win.”

Weinrick came to Trudeau in 2017 after working for more than a decade with one of the world's foremost TB researchers, William Jacobs (he was once dubbed the “TB Terminator”). For Weinrick the quest is personal: While teaching in Eritrea with the Peace Corps, a fellow teacher was hospitalized with TB. “That really illuminated the societal impact of this disease, on the places that are least able to afford it,” he says. “The personal impact is awful, but it’s a societal drain also. Tuberculosis stops people from contributing while they’re in their prime. TB reinforces the poverty cycle in the places where it is most common.”

Sheinerman, also recruited to Trudeau in 2017, is an example of how we're bringing new technical expertise into the field. As with Weinrick, he was drawn by the allure of working on a problem that could bear immediate fruit.

“It was important to me to see that this work has a direct relevance to humans,” Sheinerman says. “I think it's very likely that the next breakthrough in tuberculosis won't come from Big Pharma, but from a smaller organization such as Trudeau. And I think we're taking the right approach, with the right ingredients for success.”



## An ongoing global health crisis threatens to derail decades of advances in treating TB

Seeking solutions for emerging pathogens, such as the Zika virus



**1 billion**

Number of **people infected** each year by mosquito-borne diseases

**1 million**

Number of **people who die** each year of mosquito-borne diseases

**27,388**

Number of mosquito- and tick-borne disease **cases in U.S., 2004**

**96,075**

Number of mosquito- and tick-borne disease **cases in U.S., 2016**

**17%**

Percentage of infectious illnesses caused by **mosquito- and tick-borne disease annually.**

Source: World Health Organization, Centers for Disease Control and Prevention





# Trudeau Research Network

When the world faces emerging pathogens, Trudeau answers the call.

**T**rudeau is the partner researchers trust to translate lab breakthroughs into patient victories.

For 135 years, Trudeau has been a leader in combatting persistent infectious diseases. Our legacy provides the foundation for what we are now: A nimble, independent biomedical laboratory that is a valuable contributor in the fight against newly emerging infectious threats.

That track record engenders confidence. Today, some of the world's most prestigious research institutes are seeking to tap the expertise we've amassed at our 75,000-square-foot research laboratory in the Adirondacks. These partnerships are at the core of the Trudeau Research Network. Together, we're working to cure drug-resistant infections and find solutions for emerging pathogens, such as the Zika virus, for which no therapies exist at all.

As part of this model, leading biomedical researchers in New York, the nation and the world discover the building blocks needed to defuse emerging infectious diseases and other threats. They then leverage Trudeau's immunology expertise and biocontainment laboratory to translate those discoveries into superior candidates that merit clinical trials, and subsequently, from this stronger platform, deliver real- world treatments.

*In the Lab*

# Viral Response



## Trudeau Research Network plays key role in race to vanquish Zika

A virus that leaves no trace in many people it infects—and often results in little more than a fever or a rash—wouldn't seem a prime candidate to inspire a global race to find a cure.

But Zika isn't like most viruses. Because while most people who encounter it are barely harmed, it is a terror to pregnant women. Zika can cause a host of potentially cataclysmic birth defects, and no vaccine or medicine exists to thwart it. Yet.

With the backing of a \$1.2 million grant from the Department of Defense, Trudeau Institute Senior Principal Investigator Marcy Blackman is leading efforts to determine whether a Zika vaccine candidate can block the virus from infecting fetuses in small animal models—and, if so, whether it should move on for further clinical testing elsewhere.

That multi-pronged approach is representative of our efforts to leverage the power of the Trudeau Research Network: The vaccine was developed at the Walter Reed Army Institute of Research, is being tested at Trudeau, and, based on our findings, will be further tested by our

Veteran Trudeau researcher Marcy Blackman is leading efforts to build critical partnerships.

partners at the Texas Biomedical Research Institute. Through it all, we've worked closely with Stephen Thomas, chief of SUNY Upstate Medical University's Division of Infectious Diseases and a co-developer of the vaccine. Researchers at the University of Illinois at Chicago are also participating in the project.

"This is something that Trudeau couldn't have done on its own," says Blackman, who has been at the Institute since 1999. "But building this powerful collaboration with such accomplished partners makes me confident we can close in on a vaccine far quicker than any of us could have working apart."

Scientists still aren't sure why Zika poses such a grave threat to developing fetuses. Blackman has conducted research to see if prior exposure to the virus that causes Dengue fever makes it easier for Zika to pass through the placenta, but that work is still ongoing.

Studies like these are emblematic of Trudeau's growing focus on translational work. Instead of pursuing basic research, we're aligning with biomedical partners who can use our expertise in immunology and pathogens while solving imminent threats. To Blackman, it's a change she welcomes.

"Now, we're actually involved in the translation to biomedical solutions ourselves," says Blackman, who finds the collaborative approach accelerates the pace of progress. "So it's much more satisfying, in that sense."

At the moment, it's too early to tell whether the vaccine candidate developed by Walter Reed will be successful in preventing the disease from infecting fetuses. And while the flurry of mainstream headlines around Zika has died down somewhat in recent years—it's likely that many of the people in the places where it was rampant have already been infected, and developed antibodies to it—that just puts pressure on Blackman and others to have a vaccine candidate ready, when it resurfaces in a new area, and sparks new fears.

Blackman is optimistic that the testing regime she's developing is a model that holds hope for future collaborations between Trudeau and other partners.

"This is verification that this type of research model will really work," Blackman says. "It's hard for one place to be able to do everything. Science has really become huge, very complex, very expensive, and to have experts in different aspects of a certain problem come together is really a very efficient way of accomplishing things."



### Trudeau 3.0: Leveraging our strengths as a specialized biotechnology hub against emerging infectious threats.



# Supporting a unique network of strategic academic collaborators

---



## Dear Friends of Trudeau,

ON BEHALF OF OUR BOARD OF TRUSTEES, we want to say “thank you” to those who support the research and development currently underway at the Institute. Trudeau has captured the attention of public and private funding partners while establishing a unique network of strategic academic collaborators.

In July, we commemorated the 100th anniversary of the birth of Dr. Francis B. Trudeau, gathering with the Trudeau family and others at the Saranac Laboratory Museum. We returned to Dr. Trudeau’s lab in October, to celebrate its designation as a **Milestones in Microbiology** historic site by the American Society for Microbiology; to mark the occasion and re-affirm our 135-year legacy, TB Principal Investigator Dr. Brian Weinrick co-hosted a day-long science symposium on our campus, where a dozen experts in the field of tuberculosis shared their work.

In June we were challenged by The Cloudsplitter Foundation to raise \$100,000 from former and current Trustees to be matched dollar for dollar by the Foundation. We completed the match in four months! To me, this demonstrates a clear vote of confidence from those intimately involved with Trudeau. This money will be applied to our expanding TB research.

All of us on the board are pleased to continue shepherding Trudeau Institute into the future as a sustainable and meaningful research and development platform. We remain especially proud of our role in the community as an important economic partner and we are most grateful for Dr. Atsuo Kuki’s leadership and originality.


Thank you.

Dorothy Swern Federman, *Chair*

Kip Testwuide, *Vice Chair*

# Donors

## 2018 Contributions



### Governor's Club

(\$50,000 to \$99,999)

Mr. Irving S. Caplan Trust  
Dr. Charles W. McCutchen  
The Ambrose Monell Foundation

### Second-Century Club

(\$20,000 to \$49,999)

Mr. & Mrs. Benjamin Brewster  
Mr. Bruce McLanahan

### Founder's Club

(\$6,000 to \$19,999)

Mr. & Mrs. Alexander W. Dreyfoos  
Drs. Jay & Dorothy Federman  
Dr. Atsuo Kuki  
Mr. & Mrs. Daniel Leff  
Ms. Julie A. North & Mr. William V. Fogg  
Mr. & Mrs. Jim Sonneborn  
Mr. & Mrs. Garry Trudeau  
Dr. Tielman Van Vleck

### President's Club

(\$3,000 to \$5,999)

Anonymous  
Ms. Courtney Burke  
Dr. James C. Frauenthal  
Lola & Ray Johnson  
Lee & Nancy Keet  
Rich & Lorraine McGinn  
Dr. Lida Orzeck  
Julie & Kip Testwuide  
Mr. & Mrs. Alexander B. Trevor  
The John and Evelyn Trevor Charitable Foundation

President and Director Atsuo Kuki celebrates the Saranac Laboratory Museum's Milestone in Microbiology designation.

### Director's Club

(\$1,000 to \$2,999)

Adirondack Foundation – Evergreen Fund  
Mrs. Mary Ann Casey  
Mr. Denis Faucher  
Mr. John R. Gordon  
Mr. George P. Hanscom  
Mr. & Mrs. James Hotaling  
Sheila Rauch Kennedy  
Mr. & Mrs. Donald A. King Jr.  
Dr. Airlie C. Lennon  
Ms. Nancy Lester  
Mr. Lawrence Loeffler  
Mr. & Mrs. Clement McGillicuddy  
Mrs. Elizabeth Sonneborn  
Mr. & Mrs. Konrad Testwuide  
Ms. Patricia Y. Tsien & Mr. Thomas Cleveland  
Ms. Yi Xue  
Mrs. Janet York

### Sponsor's Club

(\$500 to \$999)

Mr. & Mrs. Barry F. Berkov  
Mr. & Mrs. Peter W. Bickford  
Mr. & Mrs. Joseph Blitt  
Jacques & Edwina DeMattos Cormier  
Dr. & Mrs. Craig B. Dumond  
William & Elaine Fearnside  
Mr. & Mrs. Henry A. Fenn  
Neil A. (Tony) Holtzman  
Dick & Bobbie Leamer  
Mr. & Mrs. J. Michael Ritchie  
Mr. & Mrs. W. McIlwaine Thompson

### Patrons

(\$250 to \$499)

Adirondack Foundation –  
Mirror Lake Inn Charitable Fund  
Ellen & Michael Bettman  
Mr. & Mrs. Edward W. Bickford  
Mr. William B. Chapin

*(continued on following page)*

**Patrons** *(continued from previous page)*  
**(\$250 to \$499)**

Mr. & Mrs. Lee Harrison Corbin  
Dr. & Mrs. Vincent A. Fischetti  
Mr. & Mrs. Stewart Greenfield  
Mr. & Mrs. John F. Heimerdinger  
Mr. & Mrs. John Hemphill  
Mr. & Mrs. William C. Janeway  
Dr. & Mrs. David A. Johnson, M.D.  
Mr. & Mrs. David P. Kirstein  
Mr. Peter McHugh & Ms. Louise McNamee  
Rice Furniture  
Ms. Mary Thill & Mr. Mark Wilson  
Mrs. Francis B. Trudeau  
Mr. & Mrs. Charles S. Von Stade Jr.

**Supporters**  
**(\$100 to \$249)**

Anonymous  
Joe & Ann Armstrong  
Mr. Perrin Babcock  
Mr. & Mrs. Matthew P. Baker  
Bernard & Lois Barrett  
Mr. Benjamin L. Chapman  
Mr. Thomas H. Delahant  
Jacques & Alice De Mattos  
Mr. Mike Emrick  
Mrs. Dorothy E. Fobare  
Mrs. Mabel E. Foote  
Mr. & Mrs. Martin Goetz  
Betty F. Hunkins  
Christopher & Audrey Hyson  
Mr. & Mrs. Wayne A. Johnston  
Michael & Sandra Kamen  
Dr. & Mrs. Woods McCahill  
Mr. & Mrs. Eugene Bradley Meyer  
Dr. & Mrs. Thomas Minehan  
Peter S. Paine Jr.  
Paul & Rosemary Reiss  
Clyde Baker & Suzanne Rice  
Harriet H. Savage  
Calvin & Christina Schmeichel  
Dr. & Mrs. Craig W. Smith  
Mr. & Mrs. Stuart Solomon  
Mrs. Elizabeth Sonneborn  
Tom & Joan Sonneborn  
Judge & Mrs. W. Neil Thomas III  
Edward & Patricia Trudeau III  
Ms. Michelle B. Trudeau & Dr. Steven G. Potkin  
Dr. Kathryn Weld-Brown  
Dr. & Mrs. David G. Welch  
Mrs. Caroline Welsh  
Mr. R.V. Whisnand  
Mr. & Mrs. Robert R. Zahm

**Friends**  
**(\$25 to \$99)**

Rip & Shirley Allen  
Lionel & Esther Arlan  
Mr. & Mrs. William Bond  
Mary & Jack Brennan

Dr. & Mrs. John Cogar  
George H. Earle  
Mr. Joseph Giordmaine  
Ms. Georgia J. Jones  
Mr. Rob Kaplan  
Mr. Arthur Kirsch  
Mr. & Mrs. Gerald Matacotta  
Sandra Mealy  
Don & Shirley Morgan  
Mr. & Mrs. Arthur G. Olver  
Bill Picotte  
Larry & Jean Poole  
Steven Sonnenberg & Margaret Worden  
Robert E. & Amy K. Sweet  
Duncan & Delphine Winter  
Fran Yardley & Burdette Parks

**All Other Contributions**

Mr. Darrell Davies  
Dr. & Mrs. Richard L. Erenstone  
Lionel & Marcia Schuman

**IN MEMORY OF**

**Bickford Family Fund**

Mr. & Mrs. Edward W. Bickford  
Mr. & Mrs. Peter W. Bickford  
Mrs. Mary Ann Casey  
Judge & Mrs. W. Neil Thomas III

**Mr. & Mrs. John F. Delahant, Jr.**

Mr. Thomas H. Delahant

**Mildred H. Duncan**

Mr. & Mrs. Matthew P. Baker

**Charles A. Janeway, Jr.**

Mr. and Mrs. Eugene Bradley Meyer

**David A. Mealy**

Sandra Mealy

**Dr. Ian Orme**

Mr. & Mrs. James Hotaling

**Dr. Francis B. Trudeau Jr.**

Edward & Patricia Trudeau  
Michelle B. Trudeau & Steven G. Potkin

**IN HONOR OF**

**Benjamin Brewster**

Dr. Tielman Van Vleck  
Mr. R.V. Whisnand

**Dr. Dorothy Federman**

Lionel & Esther Arlan  
Dr. Lida Orzeck

**Sandy Trevor**

Rich & Lorraine McGinn

**Patricia Tsien**

Robert Zahm  
George Hanscom

**Maddie's B-Day from Lucy**

Rob Kaplan



Contributions from Corporations, Foundations & Organizations

Adirondack Foundation – Evergreen Fund  
Adirondack Foundation – Keet Family Fund  
Adirondack Foundation – McLanahan Family Fund  
Adirondack Foundation – Mirror Lake Inn Charitable Fund  
Adirondack Foundation – Trevor Fund for Trudeau Institute  
The Ambrose Monell Foundation  
Bickford Family Fund  
Bionique Testing Laboratories Inc.\*  
Exxon Mobil Foundation  
The Stewart & Constance Greenfield Foundation  
The Janet Stone Jones Foundation  
Jewish Communal Fund  
The McCutchen Foundation  
The McMeel Family Foundation\*

Mountaintop Foundation  
Rice Furniture  
Ruthie’s Run  
The Sooner Foundation  
The Spiritus Gladius Foundation\*  
Staritch Foundation, Inc.  
The John & Evelyn Trevor Charitable Foundation  
Vanguard Charitable Endowment Program

*\*Received in 2017*

Although the greatest possible care has been taken preparing this recognition to our donors, there is a possibility of inaccuracies. If any are noted, please accept our apology and forward corrections.

Office of Institutional Advancement  
Trudeau Institute  
154 Algonquin Avenue  
Saranac Lake, NY 12983  
pbabcock@trudeauinstitute.org

THE FOUNDERS’ SOCIETY

To recognize our generous donors who have made a commitment to the future of the Trudeau Institute through their estate planning, we have established The Founders’ Society. This vital component of the Institute’s advancement programs is our primary mechanism for building the endowment.

The Trudeau Institute gratefully acknowledges its supporters who, through their thoughtful planned gifts, enable our research to continue into the future. If you would like to include the Institute in your future estate plans, or have already, please notify us so that we ensure your wishes are met and acknowledged properly.

Members

Richard Baker\*  
James J. Barba  
Ann Bickford\*  
Diana Bourke  
Benjamin Brewster  
Josephine T. Brune\*  
Isabel Collier Read\*  
Edwina De Mattos Cormier  
Alexander Dreyfoos  
Mildred Duncan\*

Alfred Edwards Schlesinger\*  
Dorothy Swern Federman, M.D.  
Jay Federman, M.D.  
Henry A. Fenn, Jr.  
Priscilla Goss  
George T. Hartt\*  
Elizabeth P.S. Hawkins\*  
Lola Johnson  
Raymond Johnson, Ph.D.  
Barbara J. Kirstein\*  
Robert J. Lievense  
Elizabeth Lowe

Barbara Matacotta  
Helen C. Murray\*  
D. Dean Rhoads  
Marcene S. Sonneborn  
Linda Sturgis  
Doris Tighe Coe\*  
Garry Trudeau  
Ursula Wyatt Trudeau  
Jeanne Trudeau Fenn  
Harry Voegel\*

*\*Gift realized*



We gratefully acknowledge all the federal employees who contributed through the Combined Federal Campaign to the Cancer and Aging Research Program at the Trudeau Institute.



Top: Trudeau employees and alumni gather at a reunion on July 19.

Lower: Nearly 40 people attended the first Global Health and Translational Sciences Summit in October 2018. Hosted by the Trudeau Research Network, the event drew representatives from nonprofit organizations such as the Bill and Melinda Gates Foundation, the federal government, and biotechnology and pharmaceutical companies.


## Board of Trustees

Benjamin Brewster  
Courtney Burke  
Dorothy S. Federman, M.D.  
Vincent A. Fischetti, Ph.D.  
James C. Frauenthal, Ph.D.  
Raymond N. Johnson, Ph.D.  
Atsuo Kuki, Ph.D.  
Daniel Leff  
Airlie Cameron Lennon, M.D., MPH  
Julie North  
Michael J. Parker, M.D.  
Brian A. Pollok, Ph.D.  
Marcene Sonneborn  
Konrad “Kip” Testwuide  
Tielman T. Van Vleck, Ph.D.  
Yi Xue

### HONORARY TRUSTEES

James J. Barba  
Frederick W. Beinecke  
Alexander W. Dreyfoos  
Henry “Sandy” Fenn  
Harry Jacobs Jr.  
Lawrence L. Johnson, Ph.D.  
David P. Kirstein  
Robert J. North, Ph.D.  
Alexander B. Trevor  
Garry Trudeau  
Ursula W. Trudeau

# Financial Report



The 2018 Financial Report reflects positively on many of the initiatives underway at Trudeau. Our launch of Trudeau 3.0 is validated by a significant increase in contract revenue, fueled in part from the 20% increase in science staff over the past three years. We are on schedule to eliminate our debt service in 2020 while we expand our research and development capabilities to meet growing demand. Pending alliance revenue and continuing support from New York State will allow us to increase our science expenditures by 20% this coming year and expand our educational component, including hiring a Principal Investigator to lead our partnership with Clarkson University. Our collaborations with SUNY Upstate Medical University and Albert Einstein College of Medicine have strengthened the Trudeau Research Network (TRN), which is the centerpiece of Trudeau 3.0.

## STATEMENT OF FINANCIAL POSITION

FISCAL YEARS ENDED DECEMBER 31

ASSETS	2018	2017
Cash & cash equivalents	\$ 1,360,523	2,687,141
Grants receivable	6,214,051	4,041,066
Investments, at fair value	\$ 9,604,774	11,368,633
Other assets	285,294	324,319
Property, plant and equipment, net	\$ 16,364,993	17,517,755
Funds held in trusts	3,248,454	3,694,684
<b>TOTAL ASSETS</b>	<b>37,078,089</b>	<b>39,633,598</b>
<b>LIABILITIES</b>		
Accounts Payable and accrued expenses	\$ 494,242	290,031
Capital lease obligation	920,972	1,616,944
Loan payable	\$ 375,000	675,000
<b>TOTAL LIABILITIES</b>	<b>1,790,214</b>	<b>2,581,975</b>
<b>NET ASSETS</b>		
Unrestricted:		
Available for operations	23,512,418	23,545,910
Internally designated/Edward C. Brewster Fund	\$ 4,000,000	4,000,000
Total unrestricted	27,512,418	27,545,910
Temporarily restricted	\$ 1,978,076	3,262,102
Permanently restricted:		
Endowments	\$ 1,444,261	1,444,261
Funds held in trusts	3,248,454	3,694,684
Francis B. Trudeau Chair	\$ 1,104,666	1,104,666
Total permanently restricted	5,797,381	6,243,611
<b>TOTAL NET ASSETS</b>	<b>35,287,875</b>	<b>37,051,623</b>
<b>TOTAL LIABILITIES AND NET ASSETS</b>	<b>37,078,089</b>	<b>39,633,598</b>





# Staff

## SENIOR MANAGEMENT

Atsuo Kuki, Ph.D.  
President and Director  
William B. Chapin, M.B.A.  
Chief Administrative Officer/Controller  
Perrin Babcock, M.A.  
Director of Philanthropy

## FACULTY

Marcia A. Blackman, Ph.D.  
TRN Senior Principal Immunologist and  
Leader, Viral Immunity Program  
Trudeau Principal Investigator (Influenza,  
Aging, Ferret & Vaccine Technologies)  
Deborah Brown, Ph.D.  
Manager, Joint Educational Programs  
Trudeau Principal Investigator, Vaccine  
Translational Science  
In-Jeong Kim, Ph.D.  
TRN Senior Immunologist and Leader,  
Flavivirus Research Platform  
Trudeau Principal Investigator,  
Vaccine Translational Science  
Jr-Shiuan Lin, Ph.D.  
TRN Research Scientist  
Trudeau Principal Investigator  
(Antibiotic-Resistant Bacteria [ARB]  
and Select Agents)  
William W. Reiley, Ph.D.  
Chief Scientific Officer, TICRO BioServices  
Trudeau Principal Investigator (Member, TB  
and Influenza Program)  
Felix Sheinerman, Ph.D.  
Head of Chemogenomics  
Trudeau Principal Investigator  
Brian Weinrick, Ph.D.  
TB R&D Program, Lead Investigator  
Trudeau Principal Investigator

## ADJUNCT PRINCIPAL INVESTIGATORS

Paras Jain, Ph.D.  
Albert Einstein College of Medicine  
Saravanan Thangamani, Ph.D.  
SUNY Upstate Medical University

## POSTDOCTORAL FELLOWS

Gaelle Guiewi, Ph.D.

## SENIOR RESEARCH TECHNICIANS

Tres S. Cookenham III, A.A.S.  
Debra K. Duso, A.A.S.  
Kathleen G. Lanzer, B.S.  
TRN Scientific Coordinator  
Paula A. Lanthier, A.A.S.  
Alan D. Roberts, B.S.  
Frank M. Szaba, B.S., B.A.  
Michael P. Tighe, A.A.S.  
Head, Trudeau Imaging Core

## RESEARCH TECHNICIANS

Derek Bernacki, B.S.  
FACS Coordinator  
Madeline Clark, M.S.  
Laura Cole, B.S.  
Mathew Cole, M.S.  
TICRO, Lab Manager  
Lawrence W. Kummer, B.S.  
Tricia Lang, B.S.  
Timothy Low-Beer, B.S.  
Shania Muncil, B.S.  
Kelsey Travis, B.S.

## ANIMAL TECHNICAL SERVICES

Jenna Friers, B.S.  
Animal Health/Veterinary Technician  
Jody L. Hart, B.S.  
Manager, Technical Services

**ANIMAL HUSBANDRY**

Nicole Beaudoin  
Animal Care Technician 1  
Lindsay Fagnano  
Animal Care Technician 1  
Jonathan A. Lauber  
Animal Care Technician 2/  
Sterilization Technician  
Jill E. Miller, A.A.S.  
Animal Care Technician 2  
Natalie Miller, A.A.S.  
Supervisor, EAM  
Amanda A. Schneck, B.A.  
Manager, Animal Facilities  
Toni F. Vincent  
Animal Facilities Clerk  
William T. White  
Animal Care Technician 2

**HOUSEKEEPING**

Timothy T. Harrigan, A.A.S.  
Billi Jo Symonds  
Housekeeping Supervisor  
Kerry White

**MAINTENANCE**

David L. Benham  
Maintenance Carpenter  
Shawn R. Boyer  
Boiler Operator  
Michael Carter  
Building Support Technician  
Richard P. DeMerse  
Maintenance  
Earl F. Gardner  
Machinist

Jon M. Law, Sr.  
Manager, Facilities  
Chad Mason  
Electrician  
Adam J. Mayville  
Maintenance Technician  
Bridget Parks, B.S.  
Grounds Crew/Building Support Assistant

**ADMINISTRATION**

Charles T. Billingsley, B.S.  
Manager, Computer Services  
Suzanne M. Chapman, A.A.S.  
Strategic Administrative Coordinator  
Beth Devaney, A.A.S.  
Staff Accountant/Accounts Payable  
Kristofer Friers, B.S.  
Systems Administrator  
Kathleen Keck, M.B.A.  
Executive Assistant to the President/Director  
Linda M. Madon, B.F.A.  
Payroll Specialist  
David E. Martin, A.A.S.  
Manager, Purchasing  
Simone T. McConville, B.S.  
Receptionist/Administrative Assistant  
Jeremy Ressing, B.S., B.A.  
Manager, Accounting  
Lynn M. Ryan, B.A.  
Manager, Occupational Health and Safety  
Kelly Stanyon, M.L.S.  
Associate Manager, Human Resources

Facing page: Members of Trudeau’s staff gather inside the Institute library.

Below: Members of the animal husbandry staff.



Photo credits: Split Rock Productions, Clarkson University, Mark Kurtz, Kathleen Keck.





**TRUDEAU INSTITUTE**  
Transforming Medicine Together

154 Algonquin Avenue , Saranac Lake, NY 12983  
[www.trudeauinstitute.org](http://www.trudeauinstitute.org)



## **TRUDEAU'S MISSION:**

To safeguard human health and combat 21st century global health crises, from drug-resistant TB to emerging viruses and pandemics, by empowering specialized R&D pursuits in regional and global translational science partnerships.